



Summary of the current Midcap Marvel Portfolio





Introduction

- We follow a bottom up strategy for selecting stocks in this Fund.
- However we have put the following constraints to keep the Fund focused and differentiated.
- We will never buy a stock with a market cap less than Rs 1000
- We will never enter a fund whose market cap is higher than the SEBI/AMFI limit for Midcap
- We will never have more than 25 stocks in the portfolio at any point of time (to prevent it from becoming too diversified)
- We will never go below 15 in terms of number of stocks in the portfolio to prevent the fund from becoming too concentrated.
- The following is an analysis of how have our stocks done in terms of their price performance from the day of first entry in a clients portfolio*



* We have taken the average price of a stock in the oldest client's portfolio as a base. Profit booking and additions at higher levels would have increased the avg price and vice versa



Summary	Values
1. Number of stocks	24
2. Number of multi-bagger stocks	10
3. Above average performers (30-90% returns)	7
4. Average Performers (0-30% returns)	4
5. Under Performers (<0% returns)	3
6. Average Returns	127%

Multi-bagger Stocks

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Safari Industries India Limited	Apr-22	₹ 421	₹ 2,602	518%	47%	Small Cap
2	Aegis Logistics Limited	Mar-21	₹ 174	₹ 820	371%	79%	Mid Cap
3	NCC Limited	Mar-21	₹ 59	₹ 274	364%	79%	Mid Cap
4	Radico Khaitan Limited	Mar-21	₹ 658	₹ 2,606	296%	79%	Mid Cap
5	Ganesha Ecosphere Ltd	Feb-22	₹ 622	₹ 2,016	224%	46%	Small Cap
6	Ratnamani Metals and Tubes Limited	Mar-21	₹ 1,035	₹ 3,178	207%	79%	Mid Cap
7	Ahluwalia Contracts India Limited	Mar-21	₹ 366	₹ 1,026	180%	79%	Small Cap
8	Neogen Chemicals Ltd	Mar-21	₹ 829	₹ 2,231	169%	79%	Mid Cap
9	Narayana Hrudayalaya Limited	Mar-21	₹ 487	₹ 1,273	161%	79%	Mid Cap
10	Vijaya Diagnostic Centre Ltd	Sep-23	₹ 505	₹ 1,057	109%	30%	Small Cap

Above Average Performers

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Apar Industries Limited	Feb-24	₹ 6,301	₹ 10,317	64%	13%	Mid Cap
2	Lemon Tree Hotels Limited	Dec-22	₹ 98	₹ 153	56%	38%	Small Cap
3	Protean Egov Technologies Ltd	Jan-24	₹ 1,260	₹ 1,936	54%	14%	Small Cap
4	Nuvama Wealth Management Ltd	Jun-24	₹ 5,034	₹ 6,925	38%	2%	Mid Cap
5	Mrs Bectors Food Specialities Limited	Feb-24	₹ 1,207	₹ 1,639	36%	13%	Small Cap
6	Titagarh Rail Systems Ltd	Sep-23	₹ 814	₹ 1,105	36%	30%	Small Cap
7	FDC Ltd	Sep-23	₹ 380	₹ 500	32%	30%	Small Cap

Under Performers

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Aditya Birla Capital Ltd	Sep-23	₹ 184	₹ 178	-3%	30%	Mid Cap
2	Sterling and Wilson Renewable Energy Ltd	Feb-24	₹ 573	₹ 459	-20%	13%	Small Cap
3	Aarti Industries Ltd	Mar-21	₹ 550	₹ 410	-25%	79%	Mid Cap

Multi-bagger Stocks by MCap – CY 2021

Mid Cap

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Aegis Logistics Limited	Mar-21	₹ 174	₹ 820	371%	79%	Mid Cap
2	NCC Limited	Mar-21	₹ 59	₹ 274	364%	79%	Mid Cap
3	Radico Khaitan Limited	Mar-21	₹ 658	₹ 2,606	296%	79%	Mid Cap
4	Ratnamani Metals and Tubes Limited	Mar-21	₹ 1,035	₹ 3,178	207%	79%	Mid Cap
5	Neogen Chemicals Ltd	Mar-21	₹ 829	₹ 2,231	169%	79%	Mid Cap
6	Narayana Hrudayalaya Limited	Mar-21	₹ 487	₹ 1,273	161%	79%	Mid Cap

Small Cap

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Ahluwalia Contracts India Limited	Mar-21	₹ 366	₹ 1,026	180%	79%	Small Cap

Multi-bagger Stocks by MCap – CY 2022

Small Cap

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Safari Industries India Limited	Apr-22	₹ 421	₹ 2,602	518%	47%	Small Cap
2	Ganesh Ecosphere Ltd	Feb-22	₹ 622	₹ 2,016	224%	46%	Small Cap

Multi-bagger Stocks by MCap – CY 2023

Small Cap

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Vijaya Diagnostic Centre Ltd	Sep-23	₹ 505	₹ 1,057	109%	30%	Small Cap

Above Average Performers By MCap - CY 2022

Small Cap

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Lemon Tree Hotels Limited	Dec-22	₹ 98	₹ 153	56%	38%	Small Cap

Above Average Performers By MCap - CY 2023

Small Cap

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Titagarh Rail Systems Ltd	Sep-23	₹ 814	₹ 1,105	36%	30%	Small Cap
2	FDC Ltd	Sep-23	₹ 380	₹ 500	32%	30%	Small Cap

Above Average Performers By MCap - CY 2024

Mid Cap

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Apar Industries Limited	Feb-24	₹ 6,301	₹ 10,317	64%	13%	Mid Cap
2	Nuvama Wealth Management Ltd	Jun-24	₹ 5,034	₹ 6,925	38%	2%	Mid Cap

Small Cap

Sr. No.	Stock Name	Date of Entry	Price	Price as on 31/12/2024	% Gain	BSE 500 since Inception of stock*	Remarks
1	Protean Egov Technologies Ltd	Jan-24	₹ 1,260	₹ 1,936	54%	14%	Small Cap
2	Mrs Bectors Food Specialities Limited	Feb-24	₹ 1,207	₹ 1,639	36%	13%	Small Cap



Thank You





DISCLAIMER

This presentation is intended for internal use and may contain confidential information that belongs to the sender and/or legally privileged information that is protected by the attorney-client privilege. If you are not the intended recipient of this communication, you must not disseminate copy or take any reliance on it. If you have received this message in error please notify the sender immediately, to arrange the return of the document. This document is not for public distribution and has been furnished to you solely for your information and may not be reproduced or redistributed to any other person. The manner of circulation and distribution of this document may be restricted by law or regulation in certain countries, including the United States. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions. This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. No person associated with Citrus Advisors is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this document. The material is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon. Neither Citrus Advisors, nor any person connected with it, accepts any liability arising from the use of this document. The recipient of this material should rely on their own investigations and take their own professional advice. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. We and our affiliates, officers, directors, and employees world wide, including persons involved in the preparation or issuance of this material may; (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender / borrower to such company(ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions. The same persons may have acted upon the information contained here. No part of this material may be duplicated in any form and/or redistributed without Citrus Advisors' prior written consent. No part of this document may be distributed in India or abroad. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.



For Internal Circulation Only